Semax: Research Record, Legal Status, and Where to Buy It (2026)

Where Semax came from

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by the group of N.F. Myasoedov and I.P. Ashmarin. The same group developed the related heptapeptide Selank, represented separately in Curo's Selank research-material listing.

A peer-reviewed review from that research lineage describes Semax's development and its clinical use in Russia. What that establishes is a body of published work, which is a different thing from a current legal status, and the two do not track each other across borders.

Semax therefore enters the US research conversation with an established geographic context. Its source literature is heavily Russian and Russia-linked, while the familiar US registry view is nearly blank. The mismatch is informative about where research was conducted and documented. It is not, by itself, a conclusion about the quality or outcome of that research.

What the trial registries hold

A ClinicalTrials.gov search for Semax as an intervention returns no registered studies. That result reflects where the work was done rather than whether it exists. The Russian and Russia-linked literature grew up inside a different research infrastructure, and it is not mirrored in the US registry.

The empty search result still matters. It means a researcher cannot use ClinicalTrials.gov to reconstruct a Semax development program through registered study identifiers, sponsors, endpoints, and posted results. Literature searches have to do more of the work, with close attention to source language, study design, and what each publication directly reports.

That contrast is the central feature of the record. Semax can have a history of reported clinical use in Russia, no registered intervention studies in the US database, and a place on a 2026 FDA compounding agenda at the same time. The facts coexist because they answer different questions.

The 2026 compounding review

FDA's Federal Register notice set a Pharmacy Compounding Advisory Committee meeting for July 23 and 24, 2026, under docket FDA-2025-N-6895. The July 24 schedule covered "Semax (free base), Semax acetate" and considered cerebral ischemia, migraine, and trigeminal neuralgia.

Semax was one of seven substances on the two-day agenda. The others were BPC-157, KPV, TB-500, MOTS-c, emideltide, and epitalon. The BPC-157 research-record overview and the TB-500 and thymosin beta-4 distinction cover two of those neighboring entries.

The committee recommended both forms. Voting on the free base and the acetate separately, it backed each by 8 in favor to 5 against with one abstention. Hyman, Phelps & McNamara recorded the day-two votes and McDermott Will & Schulte published a matching tally table. FDA's staff had argued against listing: the agency's briefing document for Semax called the evidence insufficient for all three evaluated uses and raised possible bleeding, immunogenicity and characterization concerns, noting that much of the supporting literature is Russian-language and thin on route and dosing detail.

The recommendation is advisory and changes nothing by itself. A substance reaches the 503A list through FDA rulemaking, and Semax is not on that list. FDA's meeting page carries the briefing documents, the questions and the archived broadcast, but no minutes and no vote table, so the tallies rest on contemporaneous reporting.

An earlier document supplies context without deciding the 2026 question. A November 10, 2021 FDA warning letter to Advanced Nutriceuticals LLC, doing business as the Guyer Institute of Molecular Medicine, said that a group of substances including Semax "were not nominated for inclusion on the 503A bulks list." It was a general compliance letter to that firm, not an action focused on Semax alone.

Is Semax legal to buy?

In the United States, Semax is legal to purchase as a research chemical for laboratory use. It is not a controlled substance and does not appear on any DEA schedule as of August 2026. What it also is not: an approved US drug, a dietary supplement ingredient, or a compound cleared for human or veterinary use.

Three boundaries define the current legal picture:

1. Research sale is lawful; human-use marketing is not. FDA has repeatedly cited peptide sellers whose sites promote human use, and courts treat that line seriously. The owner of one vendor, Paradigm Peptides, was sentenced to 70 months in federal prison in July 2026 for selling unapproved and adulterated drugs. The offense was not stocking peptides. It was selling them for human consumption while faking the paperwork.
2. Approval in another country does not transfer. Semax is registered as a medicine in Russia. That registration carries no US status, and it does not make Semax an approved drug or a lawful prescription product in the United States.
3. The compounding question is open, not settled. The July 2026 advisory vote points toward possible pharmacy compounding in the future. Until FDA completes rulemaking, no compounded or prescription Semax form exists lawfully in the US.

None of this changes how a supplier like Curo operates: Semax is sold strictly for laboratory research, not for human or animal use. Curo's research use only policy covers what that means in practice.

Where to buy Semax for laboratory research

Researchers looking for where to buy Semax face a supplier market that changed sharply in 2025 and 2026. Peptide Sciences closed in March 2026, Amino Asylum went offline after a reported federal raid in June 2025, and Paradigm Peptides ended in a criminal sentencing. Several sites now trade on those dead brand names, so the first check is not price. It is whether the company behind the storefront actually exists. Our guide to the best peptide companies in 2026 covers the current field vendor by vendor.

Five checks separate a documented Semax source from an anonymous one:

1. A lot-specific COA, published before purchase. The certificate should match the exact lot on the vial, not a generic product-page badge. The help center shows how to verify a certificate against your lot.
2. A named, independent laboratory. A COA is only as good as the lab that issued it. Court records in the Paradigm case showed the defendants admitted faking certificates outright, which is the failure mode this check exists to catch.
3. Identity and purity by more than one method. HPLC purity alone leaves an identity gap. Look for LC-MS identity confirmation and endotoxin results alongside it. Semax carries a methionine residue, so oxidation products are a real impurity class and a chromatogram is worth more than a bare percentage.
4. An identifiable company. A legal entity, a real contact route, and consistent policies. A brand name alone is not an identity, and the clone sites trading on dead vendors prove it.
5. Payment with recourse. Card payment carries buyer protection. Venmo, Zelle, and crypto-only checkouts remove it.

Curo stocks Semax 10mg in the research catalog, alongside the related Selank 10mg listing. Every lot is tested by an independent laboratory for identity (LC-MS), purity (HPLC), and endotoxin, the full testing standard is documented, and every certificate is publicly readable without an account. Orders are fulfilled from the United States, and payment options include card, crypto, Zelle, and Cash App.

How much does Semax cost?

As of August 2026, research-grade Semax in the 10mg vial size typically runs $48 to $80 from US suppliers that publish lot-matched, independently issued COAs. Cheaper vials exist, some near $35, but they cluster among suppliers with no published lot documentation, and an unverified lot is unusable as research material at any price. Curo's Semax 10mg is $74, inside that documented tier. Compare the documentation attached to the current batch first, then the price. The pre-purchase checklist walks the full sequence.

What a Semax certificate of analysis should show

A certificate of analysis should connect a specific vial lot to a specific analytical report. Begin with the lot number, then compare the product name, reported material, test date, and methods. Curo's guide to matching a certificate of analysis to its lot explains that traceability step. A certificate worth relying on shows:

• The exact lot number that appears on the vial.
• The issuing laboratory's name and report identifier.
• HPLC purity with the chromatogram, not a bare percentage.
• Mass-spectrometry identity confirmation against the expected mass near 813.9 g/mol for C37H51N9O10S.
• An endotoxin result, since a pure peptide can still carry bacterial contamination from synthesis.
• A way to verify the document independently, through a public lookup or the lab itself. Curo's COA database is open for exactly this reason.

Curo's testing standard uses exactly three methods: HPLC, LC-MS, and endotoxin testing. HPLC reports chromatographic purity. LC-MS supports molecular identity by comparing mass data with the expected compound. Endotoxin testing addresses endotoxin burden. The quality and testing standard explains why the methods answer separate questions. A purity result alone is not an identity result, and neither replaces endotoxin data.

Storage belongs to the material-integrity record, but it does not substitute for analytical testing. The guide to research-peptide and bacteriostatic-water storage describes that separate documentation layer.

For a broader framework on separating documentation from marketing when comparing suppliers, see how to evaluate research peptide companies and the companion piece on purity claims and COA batch documentation.

Further reading

Selank came out of the same institute and shares the same Pro-Gly-Pro tail, but its parent sequence is tuftsin, a fragment of the immunoglobulin G heavy chain rather than a piece of a hormone. That lineage is traced in Selank, from an antibody fragment to anxiety research.

Epitalon, the last substance on that same two-day agenda, has a research record with a similar shape and a different centre of gravity. Its telomere findings sit entirely in cell culture, and its organism-level work is a rat carcinogenesis model and a study in aged rhesus monkeys. That record is mapped in Epithalon's record, from cell culture to rhesus monkeys.

Another compound from the same research tradition has a far thinner registry footprint than Semax does. Pinealon, the EDR tripeptide, has no registered trial and no FDA UNII, and its evidence sits in cell systems and two rodent models, as mapped in Pinealon: where the EDR tripeptide has been tested.

Frequently asked questions

Is Semax legal to buy in the US?

Yes, as a research chemical for laboratory use. Semax is not a controlled substance as of August 2026. It is not an approved US drug, no lawful compounded form exists yet, and its registration as a medicine in Russia carries no US status.

Where can a researcher buy Semax?

From suppliers that publish lot-specific, independently issued COAs and operate as identifiable companies. Several well-known vendors closed or faced federal action in 2025 and 2026, and clone sites now trade on their names, so verify the company before the price. Curo lists Semax 10mg for laboratory research with every lot's certificate published openly.

How much does Semax cost?

Suppliers that publish lot-matched third-party COAs typically charge $48 to $80 for a 10mg research vial as of August 2026. Curo's 10mg vial is $74 with the lot's certificate published before purchase. Vials under that range usually come without verifiable lot documentation.

Is Semax the same thing as ACTH?

No. Four residues come from the ACTH sequence, and a synthetic Pro-Gly-Pro tail completes Semax. PubChem's structural record describes that relationship, while also distinguishing Semax from native ACTH and its corticotropic activity.

What did FDA review in July 2026?

It reviewed Semax free base and Semax acetate for the 503A bulks list, against indications of cerebral ischemia, migraine and trigeminal neuralgia, and recommended both forms by 8 votes to 5 with one abstention. That is a non-binding recommendation to FDA, not an approval and not a listing.

Does an empty ClinicalTrials.gov search erase the Russian literature?

No. It shows that the US registry does not hold a registered Semax intervention study under that search. Published literature and trial registries overlap, but they are not identical archives, especially across jurisdictions and languages.

What should a Semax certificate establish?

It should identify the material, connect the report to a lot, and show results for the methods listed. HPLC, LC-MS, and endotoxin testing each supply a different part of that record. A certificate documents analytical findings for the lot; it does not establish a research outcome.